The document is a regulatory filing submitting the transcript of an earnings call with analysts and investors held on Wednesday, August 12, 2026.
The call specifically discussed the financial performance of the Company for the quarter ended June 30, 2026 (Q1 FY27).
The filing is made pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The transcript is available on the Company's website at: https://www.caplinpoint.net/wp-content/uploads/2026/08/Q1-FY-27-Earnings-Conference-Call-Transcript.pdf
The document does not contain any statement indicating whether unpublished price sensitive information (UPSI) will or will not be shared during the call.
No financial highlights, guidance references, or presentation summaries are included in this announcement document.
No management participants or their designations are mentioned in this specific filing.
Additional Notes Section
This filing serves as a compliance submission of the transcript itself rather than an invitation to the event, which had already occurred on August 12, 2026.
No financial data or performance figures are disclosed within this announcement document.
The letter is signed by Venkatram G, General Counsel & Company Secretary (Membership No. A23989) on behalf of Caplin Point Laboratories Limited.
